Search Results

You are looking at 1 - 10 of 2,182 items for :

  • cardiovascular disease x
Clear All
Open access

Miloje Tomasevic, Srdjan Aleksandric and Sinisa Stojkovic

ABBREVIATIONS ADP - adenosine-diphosphat; ACS - acute coronary syndrome; CAD - coronary artery disease; CHD - coronary heart disease; CV - cardiovascular; CVD - cardiovascular disease; DAPT - dual antiplatelet therapy; GI - gastrointestinal bleeding; MI - myocardial infarction; NSAIDs - non-steroid anti-inflammatory drugs; PAD - peripheral artery disease; PCI - percutaneous coronary intervention; RCT - randomized controlled trial; REFERENCES 1. Aleksandric S, Tomasevic M, Dobric M, Beleslin B

Open access

Primary prevention strategy for cardiovascular disease in Lithuania

(“A Funding Programme for the Screening and Preventive Management of the High Cardiovascular Risk Individuals” – main results: 2006–2017 years)

Aleksandras Laucevičius, Egidija Rinkūnienė, Ligita Ryliškytė, Vytautas Kasiulevičius, Dalius Jatužis, Žaneta Petrulionienė, Jolita Badarienė, Rokas Navickas, Agnė Jucevičienė, Sandra Kutkienė, Svetlana Solovjova, Viktorija Andrejevaitė, Ingrida Lisauskienė, Jūratė Zupkauskienė, Roma Puronaite, Romualdas Gurevičius and Jurgita Mikolaitytė

References [1] Health Information Centre, Institute of Hygiene, Ministry of Health of The Republic of Lithuania, Causes of death 2017, Vilnius 2018. http://www.hi.lt/uploads/pdf/leidiniai/Statistikos/Mirties_priezastys/MPR_2017_isankstiniai.pdf . [2] WHO HFA Mortality database, 2009. [3] Perk J, De Backer G, Gohlke H, Graham I, Reiner Z, Verschuren M, et al. European Guidelines on cardiovascular disease prevention in clinical practice (version 2012). The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on

Open access

Harold I. Zeliger

, Straus DC. (2004). Detection of trichothecene mycotoxins in sera from individuals exposed to Stachybotrys Chartum in indoor environments. Arch Environ Health 59 (6): 317-323. Brewer JH, Thrasher JD, Straus DC, Madison RA, Hooper D. (2013). Detection of mycotoxins in patients with chronic fatigue syndrome. Toxins 5 : 605-615. Brown VJ. (2008). Dioxin exposure and cardiovascular disease: An analysis of association. Environ Health Perspect 116 (11): A491. Brunekreef B, Beelen R, Hoek G, Schouten L, Bausch-Goldbohm S

Open access

Iva Perovic Blagojevic, Tatjana Eror, Jovana Pelivanovic, Svetlana Jelic, Jelena Kotur-Stevuljevic and Svetlana Ignjatovic

References 1. Goodarzi M, Carmina E, Azziz R. DHEA, DHEAS and PCOS. J Ster Bioch 2015; 145: 213–25. 2. World Health Organisation, Global Health Observatory data, Mortality and morbidity, Cardiovascular diseases [04.09.2016.], http://www.who.int/gho/ncd/mortality_morbidity/cvd/en/ . 3. Birdsall MA, Farquhar CM, White HD. Association between polycystic ovaries and extent of coronary artery disease in women having cardiac catheterization. Ann Intern Med 1997; 126: 32–5. 4. Legro RS. Polycystic Ovary Syndrome and Cardiovascular Disease: A

Open access

Radu Sebastian Gavril

of new-onset atrial fibrillation. Am J Cardiol 111: 219–224, 2013. 7. Targher G, Valbusa F, Bonapace S et al. Nonalcoholic fatty liver disease is associated with an increased incidence of atrial fibrillation in patients with type 2 diabetes. PLoS One 8: e57183, 2013. 8. Turgut O, Yilmaz A, Yalta K, Karadas F, Birhan Yilmaz M : Gamma-glutamyltransferase is a promising biomarker for cardiovascular risk. Med Hypotheses 67: 1060–1064, 2006. 9. Ceriello A, Motz E . Is oxidative stress the pathogenic mechanism underlying insulin resistance

Open access

Maria-Magdalena Roșu, Sigina Rodica Gîrgavu, Oana Maria Corîci, Cristian Constantin and Maria Moța

://care.diabetesjournals.org/content/41/Supplement_1/S1 4. Bertoluci MC, Rocha VZ. Cardiovascular risk assessment in patients with diabetes. Diabetol Metab Syndr 9: 25, 2017. 5. Fan W. Epidemiology in diabetes mellitus and cardiovascular disease. Cardiovasc Endocrinol 6: 8-16, 2017. 6. Laakso M, Kuusisto J. Insulin resistance and hyperglycaemia in cardiovascular disease development. Nat Rev Endocrinol 10(5): 293-302, 2014. 7. Booth GL, Kapral MK, Fung K, Tu JV. Relation between age and cardiovascular disease in men and women with diabetes

Open access

Mirjana Đerić and Velibor Čabarkapa

References Hage FG, Venkataraman R, Zoghbi GJ, Perry GJ, DeMattos AM, Iskandrian AE. The scope of coronary heart disease in patients with chronic kidney disease. J Am Coll Cardiol 2009; 53: 2129-40. Wang AYM, Chan DTM, Lai KN. Cardiovascular disease in end-stage renal disease. Hong Kong J Nephrol 2006; 8: 10-16. Ronco C, Haapio M, House AA, Anavekar N, Bellomo R. Cardiorenal syndrome. J Am Coll Cardiol 2008; 52: 1527-39. Girndt M, Seibert E. Premature

Open access

Draško Pavlović, Josipa Josipović and Nikola Pavlović

-38. 12. Li C Y. Vitamin D: role in renal and cardiovascular protection. Curr Opin Nephrol Hypertens 2012; 21: 72-9. 13. Alborzi P, Patel NA, Peterson C, et al. Paricalcitol reduces albuminuria and inflammation in chronic kidney disease. Hypertension 2008; 52: 249-55. 14. Fishbane S, Chittineni H, Packman M, Dutka P, Ali N, Durie N. Oral paricalcitol in the treatment of patients with CKD and proteinuria: a randomized trial. Amer J Kidney Dis 2009; 54: 647-52. 15. De Zeeuw D, Agarwal R, Amdhal M, et al. Selective vitamin D

Open access

Lāsma Plociņa and Iveta Mintāle

intake and risk of myocardial infarction, 89 , 941–1001. Imamura, F., Lemaitre, R. N., King, I. B., Song, X. (2012). Novel circulating fatty acid patterns and risk of cardiovascular disease: The cardiovascular health study. Amer. J. Clin. Nutr. , 96 (6), 1252–1261. Iqbal, M. P. (2014). Trans fatty acids: A risk factor for cardiovascular disease. Pakistan J. Med. Sci. , 30 (1), 194–197. Jasti, S., Kovacs, S. (2010). Use of trans fat information on food labels and its determinants in a multiethnic college student population. J. Nutr. Educ. Behav

Open access

Dragana Pap, Emina Čolak, Nada Majkić-Singh, Gordana Grubor-Lajšić and Sanja Vicković

-60. 7. De Backer G, Ambrosioni E, Borch-Johensen K, et al. European guidelines on cardiovascular disease prevention in clinical practice. Third joint Task Force of Euro - pean and other Societies on Cardiovascular Disease Pre - vention in Clinical Practice. Eur Heart J 2003; 24: 1601-10. 8. Đerić M, Čabarkapa VS. Cardiovascular biomarkers in chronic kidney disease. Journal of Medical Biochemistry 2010; 29: 298-303. 9. Howie-Esquivel J, White M. Biomarkers in acute cardio vas - cular disease. J Cardiovasc Nurs 2008; 23(2): 124